Treating serious diseases by correcting mistakes in DNA has the potential to open a promising new frontier of genomic medicines. These potential new therapeutic candidates must be designed to the highest standards of precision, efficiency and specificity.

As a pioneer and leader of therapeutic genome editing, Sangamo has developed an advanced platform for developing genomic medicines. Based on natural human proteins that recognize specific DNA sequences, Sangamo’s zinc finger protein technology is designed for:

  • Single-nucleotide precision
    High design density means zinc finger-based therapeutic candidates can target almost any sequence in the genome, enabling development of treatments for technically challenging genetic conditions
  • High efficiency 
    Our therapeutic ZFNs candidates can achieve almost complete editing of their targeted locus
  • Extreme specificity
    ZFNs are engineered to engage the target site with almost no detectable off-target effects